Employer groups praised a bill aimed at boosting healthcare competition and lowering costs by banning anticompetitive insurer-provider contracts. The post Employer Groups Applaud Bill that Aims to Spur Competition in Healthcare appeared first on MedCity News.
Structure Therapeutics’ aleniglipron, a once-daily oral GLP-1 drug, led to an average 16% weight loss measured at 44 weeks. Based on these results, the biotech is preparing for Phase 3 testing expected to begin in the second half of this year. The post Structure Therapeutics Oral GLP-1 Obesity Drug Achieves ‘Injectable-Like Efficacy’ in Phase 2…
Every life sciences organization needs to consider how best to apply machine learning (ML) to RWE to support better patient outcomes. Here’s how they can ensure RWE is “ML-ready.” The post Real-World Evidence Meets Machine Learning: What It Takes to Future-Proof Evidence Generation appeared first on MedCity News.
Cardiology, in particular, offers a clear view into why so many AI solutions struggle to scale and what differentiates those that are poised for adoption. The post The Real Test for AI Diagnostics Isn’t Performance — It’s Clinical Adoption appeared first on MedCity News.
[Sponsored] Body image struggles can quietly shape how you move through the world. The post Where to Find Highly Rated Therapists for Body Image Struggles appeared first on MedCity News.
Mark Cuban, co-founder of Cost Plus Drugs, and Linda Yaccarino, CEO of the employer GLP-1 platform eMed Population Health, were at SXSW drawing a contrast between their approach to GLP-1 drugs and that of other direct-to-consumer companies. They also announced a collaboration where Cost Plus Drugs will be eMed’s distribution partner. The post At SXSW,…
Isaac Health launched an eight-week virtual program to help people reduce dementia risk through lifestyle changes like sleep, nutrition and exercise. The post Isaac Health Introduces New Virtual Program to Reduce Dementia Risk appeared first on MedCity News.
Leucovorin is now approved for cerebral folate deficiency months after FDA Commissioner Marty Makary claimed the decades-old generic drug had promise for treating autism. The FDA’s review was based on published literature and real-world evidence. The post FDA Drug Approval Marks a First for a Disease — But It’s Not Autism appeared first on MedCity…
Epic has unveiled its new “agent factory,” a platform that lets health systems build AI agents that are capable of orchestrating entire workflows across the EHR. The post Epic Is Letting Health Systems Build Their Own Agents — But Are They Ready? appeared first on MedCity News.
Congress has already granted the FDA flexibility in evaluating therapies for rare diseases, including the use of real-world evidence and natural history data when traditional large-scale trials are not feasible. The question before the FDA now is not if those tools can be applied – they can – but if the agency has the courage…